Piribo: Biosimilars: a viable market?, new publication announcement

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report called “Biosimilars: a viable market?”.

With the regulatory situation in the US in stalemate, defensive originator companies and scientific/production obstacles to overcome, generics companies must ask if this high-reward/high-risk business is worth pursuing.

The future of the pharmaceutical industry lies with biotechnology. Biotech drugs account for around 10-15% of the current pharmaceutical market, and the sector is outperforming the market as a whole.

The issue of the manufacture, approval and marketing of generic biotechnology drugs has become a major source of debate within the industry for two main reasons:

1. Cost containment. Biotech products are expensive to develop, manufacture and administer, and becoming more expensive as newer, more complex treatments are developed. The availability of generics would spur competition and hopefully reduce prices.
2. Patent expiry. Patents in the USA and Europe on the older biotech drugs have either expired or are beginning to expire over the next few years. This makes it possible for generic manufacturers to look at selling biotech drugs.

It would be wrong to say that generic biologicals are impractical however. Manufacturers in Asian, Eastern European and Latin American markets have been selling them for years. But in Western markets, the sector is a new one and there are severe difficulties for potential manufacturers. To date, only one recognisably biosimilar drug, human growth hormone, has appeared in developed markets.

How this pans out in the future is crucial for the whole market. Will a significant biosimilar market develop? Could an abridged regulatory process really benefit generic manufacturers? Is there a political will to change the status quo? Biosimilars: a viable market? is a critical new management report which addresses these and other key issues of concern.

Contents
Foreword
Executive Summary
The current state of the market for each of the major products
G-CSF
Human Insulin
Interferon
Factors in favour
Factors against
The position in the USA
The position in Europe
The position elsewhere
Who will be the players in the market?
Conclusions
Sources
Directory

“Biosimilars: a viable market?” is available from Piribo. For more information go to: http://www.piribo.com/publications/biotechnology/biosimilars_a_viable_market.html

Piribo Product ID: ESP966

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.